Hirotaka Komaba1,2, Mia Wang3, Masatomo Taniguchi4, Suguru Yamamoto5, Takanobu Nomura6, Douglas E Schaubel7, Abigail R Smith3, Jarcy Zee3, Angelo Karaboyas3, Brian Bieber3, Masafumi Fukagawa8, Francesca Tentori3,9. 1. Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan; hkomaba@tokai-u.jp. 2. The Institute of Medical Sciences, Tokai University, Isehara, Japan. 3. Arbor Research Collaborative for Health, Ann Arbor, Michigan. 4. Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 5. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan. 6. Medical Affairs, Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan. 7. Department of Biostatistics, University of Michigan, Ann Arbor, Michigan; and. 8. Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan. 9. Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
BACKGROUND AND OBJECTIVES: Prior studies have shown that sevelamer attenuates progression of arterial calcification and may reduce the risk of death compared with calcium-based phosphate binders. In clinical practice, however, sevelamer is used not only as an alternative but also as an add-on therapy in patients already being treated with calcium-based phosphate binders. We analyzed the Dialysis Outcomes and Practice Patterns Study (DOPPS) data to test the hypothesis that the initiation of sevelamer is associated with improved survival in patients on hemodialysis treated with calcium-based phosphate binders. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We included 12,564 patients from DOPPS phase 3 and phase 4 (2005-2011) who were prescribed calcium-based phosphate binders at baseline or before sevelamer treatment. Mortality risk was assessed using a sequential stratification method to identify as-yet-untreated patients who were appropriately matched to the newly treated patients on the basis of their risk of death. RESULTS: Of 12,564 patients, 2606 were subsequently treated with sevelamer hydrochloride or sevelamer carbonate. After beginning sevelamer therapy, mean serum phosphorus levels decreased by 0.3 mg/dl in the first 4 months and gradually decreased thereafter. We matched 2501 treated patients with at least one as-yet-untreated patient. Patients treated with sevelamer had a 14% lower risk for mortality compared with as-yet-untreated patients (hazard ratio, 0.86; 95% confidence interval, 0.76 to 0.97). Similar results were observed in the sensitivity analyses when changing the matching calipers or the treated and as-yet-untreated ratios, and by using propensity score matching. CONCLUSIONS: The use of sevelamer as an add-on or alternative therapy to calcium-based phosphate binders is associated with improved survival in patients on maintenance hemodialysis.
BACKGROUND AND OBJECTIVES: Prior studies have shown that sevelamer attenuates progression of arterial calcification and may reduce the risk of death compared with calcium-based phosphate binders. In clinical practice, however, sevelamer is used not only as an alternative but also as an add-on therapy in patients already being treated with calcium-based phosphate binders. We analyzed the Dialysis Outcomes and Practice Patterns Study (DOPPS) data to test the hypothesis that the initiation of sevelamer is associated with improved survival in patients on hemodialysis treated with calcium-based phosphate binders. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We included 12,564 patients from DOPPS phase 3 and phase 4 (2005-2011) who were prescribed calcium-based phosphate binders at baseline or before sevelamer treatment. Mortality risk was assessed using a sequential stratification method to identify as-yet-untreated patients who were appropriately matched to the newly treated patients on the basis of their risk of death. RESULTS: Of 12,564 patients, 2606 were subsequently treated with sevelamer hydrochloride or sevelamer carbonate. After beginning sevelamer therapy, mean serum phosphorus levels decreased by 0.3 mg/dl in the first 4 months and gradually decreased thereafter. We matched 2501 treated patients with at least one as-yet-untreated patient. Patients treated with sevelamer had a 14% lower risk for mortality compared with as-yet-untreated patients (hazard ratio, 0.86; 95% confidence interval, 0.76 to 0.97). Similar results were observed in the sensitivity analyses when changing the matching calipers or the treated and as-yet-untreated ratios, and by using propensity score matching. CONCLUSIONS: The use of sevelamer as an add-on or alternative therapy to calcium-based phosphate binders is associated with improved survival in patients on maintenance hemodialysis.
Authors: W N Suki; R Zabaneh; J L Cangiano; J Reed; D Fischer; L Garrett; B N Ling; S Chasan-Taber; M A Dillon; A T Blair; S K Burke Journal: Kidney Int Date: 2007-08-29 Impact factor: 10.612
Authors: Rachel B Fissell; Angelo Karaboyas; Brian A Bieber; Ananda Sen; Yun Li; Antonio A Lopes; Takashi Akiba; Jürgen Bommer; Jean Ethier; Michel Jadoul; Ronald L Pisoni; Bruce M Robinson; Francesca Tentori Journal: Hemodial Int Date: 2015-05-14 Impact factor: 1.812
Authors: Antonio Alberto Lopes; Lin Tong; Jyothi Thumma; Yun Li; Douglas S Fuller; Hal Morgenstern; Jürgen Bommer; Peter G Kerr; Francesca Tentori; Takashi Akiba; Brenda W Gillespie; Bruce M Robinson; Friedrich K Port; Ronald L Pisoni Journal: Am J Kidney Dis Date: 2012-03-03 Impact factor: 8.860
Authors: Geoffrey A Block; David M Spiegel; James Ehrlich; Ravindra Mehta; Jill Lindbergh; Albert Dreisbach; Paolo Raggi Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: Ronald L Pisoni; Brenda W Gillespie; David M Dickinson; Kenneth Chen; Michael H Kutner; Robert A Wolfe Journal: Am J Kidney Dis Date: 2004-11 Impact factor: 8.860
Authors: Marcelo Barreto Lopes; Angelo Karaboyas; Brian Bieber; Ronald L Pisoni; Sebastian Walpen; Masafumi Fukagawa; Anders Christensson; Pieter Evenepoel; Marisa Pegoraro; Bruce M Robinson; Roberto Pecoits-Filho Journal: Nephrol Dial Transplant Date: 2020-10-01 Impact factor: 5.992
Authors: Mario Cozzolino; Eugeniy Shilov; Zuo Li; Masafumi Fukagawa; Saeed M G Al-Ghamdi; Ronald Pisoni; Brian Bieber; Bhadrish Vallabh; Deepa H Chand Journal: Adv Ther Date: 2020-05-14 Impact factor: 3.845
Authors: Jordi Bover; Armando Aguilar; Carolt Arana; Pablo Molina; María Jesús Lloret; Jackson Ochoa; Gerson Berná; Yessica G Gutiérrez-Maza; Natacha Rodrigues; Luis D'Marco; José L Górriz Journal: Front Med (Lausanne) Date: 2021-05-19